As the FTSE 100 index experiences fluctuations due to global economic pressures, particularly from China’s slower-than-expected recovery, investors are keeping a close eye on potential opportunities within the UK market. In such an environment, identifying stocks that may be trading below their estimated value can provide a strategic advantage for those looking to capitalize on market inefficiencies and long-term growth potential.
Top 10 Undervalued Stocks Based On Cash Flows In The United Kingdom
Name
Current Price
Fair Value (Est)
Discount (Est)
Tristel (AIM:TSTL)
£3.675
£6.88
46.6%
THG (LSE:THG)
£0.3496
£0.68
48.5%
SDI Group (AIM:SDI)
£0.78
£1.54
49.3%
RHI Magnesita (LSE:RHIM)
£26.95
£52.70
48.9%
Mitie Group (LSE:MTO)
£1.742
£3.25
46.5%
M&G (LSE:MNG)
£2.98
£5.53
46.1%
GB Group (LSE:GBG)
£2.122
£3.96
46.4%
FDM Group (Holdings) (LSE:FDM)
£1.124
£2.15
47.8%
Eurocell (LSE:ECEL)
£1.06
£2.04
47.9%
Entain (LSE:ENT)
£5.67
£10.25
44.7%
Let’s explore several standout options from the results in the screener.
Overview: Serica Energy plc, with a market cap of £1.09 billion, is engaged in identifying, acquiring, and exploiting oil and gas reserves in the United Kingdom.
Operations: The company’s revenue primarily comes from its oil and gas exploration, development, production, and related activities, amounting to $601.43 million.
Estimated Discount To Fair Value: 26.8%
Serica Energy is trading 26.8% below its estimated fair value and more than 20% below future cash flow value, suggesting it may be undervalued based on cash flows. Despite recent volatility and a net loss of US$51.82 million in 2025, revenue is forecast to grow faster than the UK market at 13.9% annually, with earnings expected to rise by 30.93% per year as profitability returns within three years. The company’s acquisition in the Greater Laggan Area enhances growth prospects significantly.
AIM:SQZ Discounted Cash Flow as at Apr 2026
Overview: AstraZeneca PLC is a biopharmaceutical company that specializes in the discovery, development, manufacture, and commercialization of prescription medicines, with a market cap of £216.70 billion.
Operations: The company’s revenue is primarily derived from its pharmaceuticals segment, which generated $58.74 billion.
Estimated Discount To Fair Value: 41.3%
AstraZeneca is trading £139.72, significantly below its estimated future cash flow value of £237.83, indicating potential undervaluation based on cash flows. Despite high debt levels, the company’s earnings are projected to grow at 13.1% annually, outpacing the UK market’s growth rate. Recent positive trial results for Ultomiris and tozorakimab in rare diseases and COPD enhance its product pipeline strength, although executive changes may introduce some strategic shifts in leadership focus.
LSE:AZN Discounted Cash Flow as at Apr 2026
Overview: Morgan Advanced Materials plc is a company that manufactures and sells a range of carbon and ceramic products, with a market cap of approximately £593.02 million.
Operations: The company’s revenue is derived from three primary segments: Thermal Products (£349.90 million), Performance Carbon (£307.30 million), and Technical Ceramics (£341.90 million).
Estimated Discount To Fair Value: 41.4%
Morgan Advanced Materials is trading at £2.15, significantly below its estimated future cash flow value of £3.66, highlighting potential undervaluation based on cash flows. Despite a high debt level and recent declines in sales and net income, the company is forecast to become profitable within three years with earnings growth expected at 60.43% annually. However, revenue growth projections remain modest at 2.9% per year, trailing the broader UK market’s pace.
LSE:MGAM Discounted Cash Flow as at Apr 2026 Where To Now? Curious About Other Options?
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include AIM:SQZ LSE:AZN and LSE:MGAM.
This article was originally published by Simply Wall St.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com